2 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 3 | 1 | Unknown 1 |
Follow Recurrent Rectal Cancer: new trials by email Literature Review of Recurrent Rectal Cancer trials Research Report on Recurrent Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer PD-1 antibody, Capecitabine, 5FU - Recurrent Rectal Cancer | Phase 2 | Unknown | Fudan University | 93 | 2022-11-30 | 2024-10-01 |
| SGM-101 in Locally Advanced and Recurrent Rectal Cancer SGM-101 - Rectal Cancer, Recurrent Rectal Cancer | Phase 2 / Phase 3 | Unknown | Leiden University Medical Center | 203 | 2019-10-22 | 2020-11-24 |
Rectal Neoplasms (2)
Colorectal Neoplasms (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2)
Bevacizumab (1) · Capecitabine (1) · Cetuximab (1) · Fluorouracil (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Radiation (1) · raltitrexed (1) · spartalizumab (1) · toripalimab (1)
Fudan University (1) · Leiden University Medical Center (1)
China (1) · Netherlands (1)